Opthea Limited (NASDAQ:OPT – Get Free Report) shares saw an uptick in trading volume on Friday . 84,166 shares changed hands during mid-day trading, an increase of 204% from the previous session’s volume of 27,659 shares.The stock last traded at $4.87 and had previously closed at $4.60.
Wall Street Analysts Forecast Growth
Separately, Canaccord Genuity Group upgraded shares of Opthea to a “strong-buy” rating in a research report on Tuesday, December 17th.
View Our Latest Stock Report on OPT
Opthea Stock Performance
Institutional Investors Weigh In On Opthea
An institutional investor recently bought a new position in Opthea stock. Twin Lakes Capital Management LLC purchased a new stake in Opthea Limited (NASDAQ:OPT – Free Report) in the 3rd quarter, according to its most recent filing with the SEC. The fund purchased 19,806 shares of the company’s stock, valued at approximately $81,000. Institutional investors own 55.95% of the company’s stock.
Opthea Company Profile
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
See Also
- Five stocks we like better than Opthea
- How to Buy Cheap Stocks Step by Step
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- How to Calculate Stock Profit
- 3 Buy-and-Hold Stocks for Long-Term Growth
- When to Sell a Stock for Profit or Loss
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for Opthea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opthea and related companies with MarketBeat.com's FREE daily email newsletter.
